NCT07528027

Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 for the Treatment of Hypertension in Participants With Obesity or Overweight

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 648 (estimated)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;

Conditions

• Hypertension With Overweight or Obesity

Interventions

Type	Name	Description
DRUG	HRS-7535	HRS-7535
DRUG	Placebo	Placebo

Timeline

• Start date: 2026-05-01
• Primary completion: 2027-12-01
• Completion: 2028-01-01
• First posted: 2026-04-14
• Last updated: 2026-04-14

Locations

2 sites across 1 country: China